Trial Profile
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Retifanlimab (Primary)
- Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Acronyms POD1UM-203
- Sponsors Incyte Corporation
- 12 Jul 2022 Status changed from active, no longer recruiting to completed.
- 30 May 2022 This trail has been completed in Hungary, according to European Clinical Trials Database record.
- 13 Apr 2022 Planned End Date changed from 6 Jul 2022 to 5 Jun 2022.